Methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate (BioDeep_00000175623)
human metabolite blood metabolite
代谢物信息卡片
化学式: C25H26N4O4 (446.19539560000004)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 0.43%
分子结构信息
SMILES: CC(C(CC1=CC(=CC=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-]
InChI: InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)
描述信息
同义名列表
5 个代谢物同义名
Methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoic acid; Methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate; 4-[4-({3-[(3-carbamimidoylphenyl)methyl]-4-methoxy-4-oxobutan-2-yl}carbamoyl)phenyl]pyridin-1-ium-1-olate; 3-[2-(Methoxycarbonyl)-3-[4-[(pyridine 1-oxide)-4-yl]benzoylamino]butyl]benzamidine; Otamixaban
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
文献列表
- Edith A Nutescu, Karen Pater. Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.
IDrugs : the investigational drugs journal.
2006 Dec; 9(12):854-65. doi:
NULL
. [PMID: 17139573] - Markus Hinder, Annke Frick, Pierre Jordaan, Galina Hesse, Alexander Gebauer, Jochen Maas, Anne Paccaly. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Clinical pharmacology and therapeutics.
2006 Dec; 80(6):691-702. doi:
10.1016/j.clpt.2006.09.002
. [PMID: 17178269] - Anne Paccaly, Annke Frick, Shashank Rohatagi, Jingli Liu, Umesh Shukla, Ronald Rosenburg, Markus Hinder, Bradford K Jensen. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure.
Journal of clinical pharmacology.
2006 Jan; 46(1):37-44. doi:
10.1177/0091270005281817
. [PMID: 16397282] - Anne Paccaly, Annke Frick, Marie-Laure Ozoux, Valeria Chu, Ronald Rosenburg, Markus Hinder, Umesh Shukla, Bradford K Jensen. Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects.
Journal of clinical pharmacology.
2006 Jan; 46(1):45-51. doi:
10.1177/0091270005281818
. [PMID: 16397283] - Anne Paccaly, Marie-Laure Ozoux, Valeria Chu, Kelly Simcox, Vanessa Marks, Geneviève Freyburger, Michel Sibille, Umesh Shukla. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
Thrombosis and haemostasis.
2005 Dec; 94(6):1156-63. doi:
10.1160/th05-05-0347
. [PMID: 16411387] - V Chu, K Brown, D Colussi, J Gao, J Bostwick, C Kasiewski, R Bentley, S Morgan, K Guertin, H W Pauls, Y Gong, A Zulli, M H Perrone, C T Dunwiddie, R J Leadley. Pharmacological characterization of a novel factor Xa inhibitor, FXV673.
Thrombosis research.
2001 Aug; 103(4):309-24. doi:
10.1016/s0049-3848(01)00328-0
. [PMID: 11562341]